Hsbc Holdings PLC Has $326,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Hsbc Holdings PLC increased its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) by 89.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 103,470 shares of the company’s stock after purchasing an additional 48,960 shares during the quarter. Hsbc Holdings PLC’s holdings in Ginkgo Bioworks were worth $326,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DNA. Atria Wealth Solutions Inc. bought a new position in shares of Ginkgo Bioworks in the second quarter worth about $30,000. Lake Street Financial LLC bought a new position in Ginkgo Bioworks in the 3rd quarter worth approximately $31,000. Avantax Advisory Services Inc. acquired a new position in shares of Ginkgo Bioworks during the third quarter worth approximately $31,000. Cetera Investment Advisers bought a new stake in shares of Ginkgo Bioworks in the second quarter valued at approximately $33,000. Finally, Van ECK Associates Corp grew its stake in shares of Ginkgo Bioworks by 104.6% in the third quarter. Van ECK Associates Corp now owns 12,740 shares of the company’s stock worth $39,000 after acquiring an additional 6,512 shares during the last quarter. Institutional investors own 61.83% of the company’s stock.

Insider Activity at Ginkgo Bioworks

In other Ginkgo Bioworks news, insider Reshma P. Shetty sold 37,650 shares of the firm’s stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $1.65, for a total transaction of $62,122.50. Following the completion of the transaction, the insider now owns 13,993,504 shares in the company, valued at $23,089,281.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Barry Canton sold 98,934 shares of the stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $1.89, for a total transaction of $186,985.26. Following the completion of the sale, the insider now owns 19,316,149 shares in the company, valued at approximately $36,507,521.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Reshma P. Shetty sold 37,650 shares of the business’s stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $1.65, for a total transaction of $62,122.50. Following the completion of the transaction, the insider now owns 13,993,504 shares in the company, valued at $23,089,281.60. The disclosure for this sale can be found here. Insiders have sold a total of 4,910,092 shares of company stock valued at $8,514,185 over the last quarter. 17.47% of the stock is owned by company insiders.

Ginkgo Bioworks Trading Up 1.5 %

Shares of DNA stock opened at $1.32 on Thursday. The firm has a fifty day moving average of $1.70 and a 200-day moving average of $2.21. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of -1.02 and a beta of 0.91. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $1.22 and a 52-week high of $4.91. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71.

Analyst Upgrades and Downgrades

Several research firms recently commented on DNA. Berenberg Bank assumed coverage on shares of Ginkgo Bioworks in a research note on Monday, November 28th. They set a “buy” rating and a $6.00 target price for the company. BTIG Research reduced their target price on shares of Ginkgo Bioworks from $4.00 to $3.00 in a research note on Sunday. Finally, Raymond James lowered their price target on Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.39.

Ginkgo Bioworks Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.